• VIX
    Loading…
    —
    —
    ——
  • BIST 100
    Loading…
    —
    —
    ——
  • UST Yield 10y
    Loading…
    —
    —
    ——
  • S&P 500
    Loading…
    —
    —
    ——
  • Brent Oil
    Loading…
    —
    —
    ——
  • XAU/TRY
    Loading…
    —
    —
    ——
  • EUR/TRY
    Loading…
    —
    —
    ——
  • USD/TRY
    Loading…
    —
    —
    ——
  • XAU/USD
    Loading…
    —
    —
    ——
  • EUR/USD
    Loading…
    —
    —
    ——

/

Category

/

Bayer's $7.25bn Roundup settlement is finally approved, but thousands get less than they hoped

Bayer's $7.25bn Roundup settlement is finally approved, but thousands get less than they hoped

Photo: SHOX ART

Bayer just got a court to sign off on a $7.25 billion settlement over claims that its Roundup weedkiller causes cancer, and the German company is calling it a turning point. For the tens of thousands of Americans who say they got sick from using it, the approval means money is finally coming. It also means most of them will receive less than the people who settled years ago.

Judge Timothy Boyer of a St. Louis state court approved the deal on Friday, finding it "fair, reasonable and adequate." He overruled objections from some plaintiffs who argued the payout structure was unfair, noting that the alternative was worse: cancer victims, including those with terminal diagnoses, could otherwise wait "an indeterminate number of years" to see any money at all.

How Bayer got here

This case has roots in a $63 billion decision. In 2018, Bayer bought Monsanto, the company that makes Roundup. Almost immediately, the lawsuits began piling up, and Bayer's stock started falling. By the time of Friday's ruling, shares had dropped 46% since the acquisition. The company had faced roughly 65,000 claims from people who said they developed cancer, most commonly non-Hodgkin lymphoma, after using Roundup at home or at work.

Bayer tried to settle earlier. In 2020, it paid $10.9 billion to resolve a large chunk of the litigation. But a separate $1.25 billion settlement to cover future claims never got court approval, leaving the company exposed to new lawsuits for years afterward. The deal approved Friday, announced in February, is meant to close that gap by resolving nearly all current and future Roundup claims in the US.

A Supreme Court ruling changed the math

The timing of the approval matters. Five months ago, the US Supreme Court ruled 7 to 2 in favor of Bayer in a case brought by a Missouri man, John Durnell, who blamed glyphosate, the active ingredient in Roundup, for his non-Hodgkin lymphoma. The court held that a federal law regulating pesticides blocked the kind of state-law "failure to warn" claims that had been the core of most Roundup lawsuits.

That ruling did not vindicate Roundup's safety record. It simply narrowed the legal path for anyone still trying to sue. Christopher Seeger, a lawyer representing many plaintiffs, said the decision "narrowed the ability of Roundup victims to pursue claims in court." In plain terms, the Supreme Court made settlement the best available option for most claimants, which almost certainly made it easier for Judge Boyer to call the deal fair.

Bayer has consistently maintained that Roundup and glyphosate are safe, citing decades of studies. That scientific debate is not settled in a courtroom, and regulatory agencies in different countries have reached different conclusions about glyphosate's cancer risk.

What it means for people who got sick

For the people who brought these claims, the outcome is complicated. Those who settled in earlier rounds, particularly around 2020, generally received larger individual payouts. The plaintiffs approving this settlement are, in many cases, accepting less, partly because the Supreme Court ruling weakened their legal leverage.

About 200 cases were left out of the settlement and remain in federal court. Bayer says the Supreme Court decision gives it strong grounds to defend those cases.

For Bayer, the approval is a genuine relief. The company's CEO, Bill Anderson, called it "a decisive milestone" in managing the litigation risk that has shadowed the company since the Monsanto deal. Whether it fully repairs the damage to the stock and the balance sheet depends on how quickly the payouts move and whether the federal cases create fresh exposure.

What the Roundup saga illustrates more broadly is how long the gap can be between harm and remedy when mass litigation collides with corporate resources and appellate courts. Nearly a decade passed between the acquisition that brought these lawsuits into Bayer's hands and a judge finally saying the deal was done. For the people who are terminally ill, that gap was not just financial. It was time.

We bring you clear, incisive analysis on economics, markets, and global affairs—cutting through noise to deliver insight that actually matters. Our publication is built for readers who want to understand why events unfold the way they do.

contact@theequilibrium.global

Newsletter

Join now!

By signing up, you agree to our Privacy Policy

© 2025 The Equilibrium

We bring you clear, incisive analysis on economics, markets, and global affairs—cutting through noise to deliver insight that actually matters. Our publication is built for readers who want to understand why events unfold the way they do.

contact@theequilibrium.global

Newsletter

Join now!

By signing up, you agree to our Privacy Policy

© 2025 The Equilibrium

We bring you clear, incisive analysis on economics, markets, and global affairs—cutting through noise to deliver insight that actually matters. Our publication is built for readers who want to understand why events unfold the way they do.

contact@theequilibrium.global

Newsletter

Join now!

By signing up, you agree to our Privacy Policy

© 2025 The Equilibrium